CSN Login
Members Online: 13

You are here

PARP drug

2timothy1 7's picture
2timothy1 7
Posts: 348
Joined: Jan 2012

I know many of our sisters are on PARP trials . This is fantastic news on the phase 2 PARP BMN 673 for breast cancer. Yes, breast, but read on. I was told that the OVCA results were expected to be released shortly and are as good or better. It seems the BMN 673 had a 50% response rate with numerous "complete" responses. The results were so awesome that they are going straight to phase 3 -- like NOW -- for breast and ovarian, and once phase 3 is out, FDA is expected to fast track it. Could be available by prescription by January!


Here is the link: http://www.benzinga.com/news/13/07/3784909/biomarin-provides-bmn-673-progra m-uupdated

I found this info on another site and wanted to pass along to everyone.

Alexandra's picture
Posts: 1311
Joined: Jul 2012

I believe that PARP inhibitors are the future of OVCA treatment, with more targeted approach and gentler on the body than conventional chemo. FDA approval can't come soon enough!

Watch 42 min long video "Prospects for Targeted Therapy in Ovarian Cancer" presented by Michael Birrer, MD, PhD

He talks about PARP inhibitors from 13:37 till 22:30 min. Bring popcorn.


Pamela B's picture
Pamela B
Posts: 108
Joined: Jan 2013

Great information.  Hopefully I won't need it since I am celebrating my big 2 months of remission (got to celebrate what you can!!!)  But I file this kind of information away "just in case."   Thanks so much to both of you for sharing the knowledge that might help us all.

Posts: 5
Joined: Aug 2013

Thanks for your post.  I am trying to get access to the drug and am interested in knowing if you have any further information about when the drug may be available and whether there are any ovarian trials planned.


Thanks so much for sharing!  i am trying to get access to the drug on a compassionate or emergency use basis.



Alexandra's picture
Posts: 1311
Joined: Jul 2012

Hello Andrea,

Go to clinicaltrials.gov, search by drug name and you will see current trials, eligibility requirements and contact information to enroll.

Examples (there are more):

NCT01286987 Study of BMN 673, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors
NCT01844986 Olaparib Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy
NCT01237067 Olaparib in Combination With Carboplatin for Refractory or Recurrent Women's Cancers
NCT01445418 AZD2281 Plus Carboplatin to Treat Breast and Ovarian Cancer
NCT01847274 A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer
NCT01690598 Veliparib and Topotecan for Relapsed Ovarian Cancer With Negative or Unknown BRCA Status
Subscribe to Comments for "PARP drug"